Last reviewed · How we verify
SPG601
At a glance
| Generic name | SPG601 |
|---|---|
| Sponsor | Spinogenix |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Effects and Safety of SPG601 for the Treatment of Fragile X Syndrome in Male Participants (PHASE2, PHASE3)
- Study of SPG601 in Adult Men With Fragile X Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPG601 CI brief — competitive landscape report
- SPG601 updates RSS · CI watch RSS
- Spinogenix portfolio CI